<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>beta(2)-<z:chebi fb="2" ids="17089">Glycoprotein</z:chebi> I, an anionic <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding 50-kDa plasma protein, circulates in the plasma at a concentration of 30-200 microg/ml </plain></SENT>
<SENT sid="1" pm="."><plain>Its physiological role remains uncertain, but an important clue to this role is suggested by the finding that antibodies to this protein are frequently found in patients with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>beta(2)-<z:chebi fb="2" ids="17089">Glycoprotein</z:chebi> I belongs to the complement control protein (<z:chebi fb="97" ids="35889">CCP</z:chebi>) superfamily with five <z:chebi fb="97" ids="35889">CCP</z:chebi> domains </plain></SENT>
<SENT sid="3" pm="."><plain>The fifth <z:chebi fb="97" ids="35889">CCP</z:chebi> domain of beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I has a unique structure and contains a stretch of positively charged amino acids that mediates the binding to <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>This interaction may mediate the clearance of anionic <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-containing surfaces from the circulation </plain></SENT>
<SENT sid="5" pm="."><plain>Mutations in this domain affect its binding to <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>We have identified a patient with <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> who is a compound heterozygous for two mutations in the fifth <z:chebi fb="97" ids="35889">CCP</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>One mutation is located in exon 7 (codon 306), and the second mutation is in exon 8 (codon 316) </plain></SENT>
<SENT sid="8" pm="."><plain>The mutant beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I was present in <z:mpath ids='MPATH_458'>normal</z:mpath> quantities in his plasma but did not bind to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>He had <z:hpo ids='HP_0004850'>recurrent deep vein thrombosis</z:hpo> and <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> at age 28 and a thrombotic <z:hpo ids='HP_0001297'>stroke</z:hpo> at age 35, with no other identifiable risk factor for a <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>This report offers some insight into the mechanism of formation of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and suggests the possible role of the deficiency of beta(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I in the pathogenesis of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>